Debt-to-equity in % of Verona Pharma plc from Q3 2021 to Q2 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Verona Pharma plc quarterly Debt-to-equity history and change rate from Q3 2021 to Q2 2025.
  • Verona Pharma plc Debt-to-equity for the quarter ending 30 Jun 2025 was 133 %, a 187% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Verona Pharma plc Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q2 2025 133 +86.6 +187% 30 Jun 2025
Q1 2025 149 +131 +720% 31 Mar 2025
Q4 2024 117 +101 +653% 31 Dec 2024
Q3 2024 82.9 +70 +540% 30 Sep 2024
Q2 2024 46.2 +32.1 +227% 30 Jun 2024
Q1 2024 18.2 -0.17 -0.93% 31 Mar 2024
Q4 2023 15.5 -6.22 -28.6% 31 Dec 2023
Q3 2023 13 -13.2 -50.5% 30 Sep 2023
Q2 2023 14.1 -14.6 -50.9% 30 Jun 2023
Q1 2023 18.3 -11.7 -38.9% 31 Mar 2023
Q4 2022 21.8 -2.16 -9.03% 31 Dec 2022
Q3 2022 26.2 +6.38 +32.2% 30 Sep 2022
Q2 2022 28.7 30 Jun 2022
Q1 2022 30 31 Mar 2022
Q4 2021 23.9 31 Dec 2021
Q3 2021 19.8 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.